chloroacetic acid/sulfosalicylic acid as a fixative, as judged by the sharpness and intensity of the fixed bands.
control materials analytical error
Methodologic differences among assays of carcinoembryonic antigen (CEA) have been well documented (1) (2) (3) (4) (5) (6) (7) . These discrepancies may be caused by differences in antibody specificity, reference standards, extraction procedures, separation methods, data-reduction methods, or numerous other possibilities. French investigators showed that four reference preparations of CEA responded differently in various European assay systems (2) , and Davidson et al. showed that differences in three British assays were due to the characteristics of the assay systems rather than differences in standards (5) . The Roche polyclonal RIA procedure has been shown to agree on the average with Abbott polyclonal enzyme immunoasaay (EIA), with discordant results (both larger and smaller) being found for 16 to 21% of the patients (4) (5) (6) (7) . However, cross-comparison of the standards used in these assays shows larger discrepancies (8) .
Major interassay differences have been presented in the test results for the proficiency-testing specimens for CEA distributed by the College of American Pathologists (CAP). These differences are larger than would be expected from reported comparisons of the analytical methods. Because we wondered if these differences were related to the different sources of CEA material used to prepare the specimens for the surveys, we divided the CAP surveys according to the source of CEA used for making the test specimens and compared the test results reported for various analytical procedures. In addition, we compared the large proportional differences found when proficiency samples and control material were measured with different lots of Abbott polyclonal reagent and the smaller random differences encountered when the same reagents were used to measure fresh samples.
Materials and Methods
The summary statistics for test results from participants in the 1983, 1984, and 1985 Ligand Assay Proficiency Surveys were obtained from the CAP. The specimens for these surveys were manufactured by the Diagnostic Division of CooperBiomedical, Malvern, PA, by adding purified CEA to serum that had been converted from plasma by the addition of calcium and thrombin, followed by separation of the coagulum, dialysis to remove calcium, and refortification of salts to physiological limits. Three different sources of CEA were used to make the proficiency specimens. Ki through K9 of the 1984 series, we compared the Abbott-EIA, Abbott-RIA, and the Roche Diagnostics/Indirect Assay (with a Clinetics columns) because these were the procedures most commonly used by the survey participants. Beginning in the last quarter of 1984, we included two additional assay systems in our analysis: the Abbott-EIA Monoclonal and the Hybritech-R assay (Hybritech, La Jolla, CA). We compared the average reported survey values from various combinations of these assay systems by analyzing the slopes and intercepts calculated from least squares linear regression. Student's t-tests were used to test if the slopes of the regression lines differed from unity.
In our second investigation of CEA methodological discrepancies, we examined lot-to-lot differences in the Abbott-EIA polyclonal reagent supplied in the spring of 1984. The concentrations of CEA in the 1983 CAP survey specimens, as measured with lot no. 62-689Hz reagent, were compared with the concentrations measured with prior lots of reagent. In addition, we compared values obtained by using these different lots of Abbott EIA reagents for measuring both commercial and locally prepared quality control pools and 102 patients' specimens. The commercial control pools (Hyland Diagnostics, Costa Mesa, CA) were: Omega I (lot no. 4814F001B), Omega H (lot no. 4824F001B), and Omega ifi (lot no. 4834F001B). The in-house control pools were made by adding a perchioric acid extract of a liver metastasis of colon carcinoma into blood bank plasma that had been converted to serum by the addition of calcium and thrombin. The control pools, proficiency samples, and patients' specimens were stored frozen at -20 #{176}C for one to 12 months between analyses.
Resufts
We found that the differences in the measurements of CEA varied systematically with the analytical method and the source of the CEA material used in the surveys. results were 30% greater than the Hybritech-R results (p <0.001), the Abbott EIA monoclonal results were 11% greater than the Hybritech-R (p -0.01), and the Roche RIA results with Clinetics columns were only 22% as great as the Hybritech-R values (p <0.001).
We found proportional differences between measurements obtained with different lots of reagent from the Abbott EllA polyclonal assay for control specimens made from partly purified CEA preparations, but not for patients' specimens. Measurements made with lot no. 62-689HZ and subsequent lots produced values for the 1983 CAP survey material, the commercial control specimens, and the in-house control specimens about twice as great as the values measured with prior lots of reagents (slopes = 2.09, 1.95, and 1.86, respectively; p <0.001 for each). This proportional difference was not noted with 102 patients' specimens, which showed random variations but no systematic differences between reagent systems (see Figure 3) as an upward bias of the regression line. The scatter of the patients' values about their regression line suggests that the two patients' values lying on the regression line for the controls probably represents assay variation rather than results for patients with a different form of CEA. Unfortunately, we could not confirm these discrepant patients' values by retesting owing to the unavailability of the previous set of reagents.
Discussion
Because CEA is defined in terms of its physical chemistry and immunological properties, a variety of different substances may be included under that definition; this heterogeneity may account for the differences we have noted in this study. CEA, characterized as a glycoprotein with a molecular mass of 186 000 Da and 45 to 57% carbohydrate, is soluble in 1 molJL perchloric acid and in half-saturated ammonium sulfate (9, 10). It gives a homogeneous band of (3 mobility on standard electrophoretic systems, but is heterogeneous by isoelectric focusing, with a major band at pH 4.5. The charge heterogeneity of various CEA preparations has been attributed, in part, to variations in sialic acid content of the molecule. The amino acid sequence of CEA is relatively constant, but the carbohydrate moieties are variable (11, 12) .
Studies with monoclonal antibodies indicate that CEA contains no more than five or six antigenic sites (13) (14) (15) (16) (17) (18) . However, many antisera to CEA cross react with glycoproteins other than CEA (19), and glycosaminoglycans can interfere with some assay systems (20) .
The quantitative differences between the Roche and Abbott polyclonal assays demonstrated with the CAP survey specimens may be related to differences in the assay standards. When the Schandls assayed by the Abbott polyclonal method the Roche standard equivalent to 125 tg/L, only 37 g1L (28%) was recovered (8). Conversely, the Abbott 10 and 20 g/L standards were measured as 1.0 and 2.3 igfL, respectively, in the Roche assay. In our study, most of the CAP survey specimens produced higher values by the Abbott assay than by the Roche assay. According to the Schandls' data, the Abbott results would have been even higher if they had been based on the Roche standard. On the other hand, the values obtained with the Roche assay would have been higher, coming closer to the Abbott values, if they had been based on the Abbott standards. This implies that the CAP survey specimens are more like the Abbott standards than the Roche standards. This is not unreasonable, considering that the 1985 CEA source material was from Abbott, but it is interesting that the 1983 CEA material obtained from Roche also produced higher results in the Abbott assay. However, the difference in standards probably is not the major explanation for the differences between these assays because both sets of standards produce similar average CEA measurements for patients' specimens (4) (5) (6) (7) .
In general, the quantitative differences among assay systems are greater for standard or control preparations than for patients' specimens. The differences for patients' results appear to be randomly distributed, with both overand underestimation (4) (5) (6) (7) , whereas the standard reference preparations have more systematic, proportional betweenassay differences. The differences found for specimens prepared from the purified CEA could represent a random selection process, in which the particular tumors selected for making the CEA preparations correspond to the extreme values in the patient-comparison studies. This, however, is unlikely because purified CEA from two vastly different sources showed the similar systematic differences among the assay systems. More likely, these differences may be related to changes in CEA molecules caused by the processes used to produce the control specimens. Perhaps the purification procedures used to isolate the CEA from the tissue sources select out certain antigemc subclasses of CEA, thereby magnifying the methodologic assay differences. We do not now know the immunochemical causes of these differences, but perhaps future investigations with highly specific monoclonal antibodies will help resolve or reconcile these assay differences.
